In aged C57BL/6 mice, daily oral Anamorelin produced modest increases in body weight and fat mass compared with PBS-treated controls. In male non-cancer-bearing mice receiving Anamorelin by oral gavage, the reported body-weight comparison with vehicle controls was not statistically significant. In female athymic nude mice bearing A549 tumors, daily oral Anamorelin increased percentage body-weight change significantly at the higher tested doses compared with water controls, while the lowest tested dose did not. In tumor-bearing BALB/c mice, daily Anamorelin by oral gavage had no effect on tumor growth during treatment. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Anamorelin and body weight in aged mice
Animal study · 23‐month‐old C57BL/6 mice [1]
Aged C57BL/6 mice received Anamorelin daily by oral administration. Treatment produced modest increases in body weight and fat mass compared with PBS-treated controls.
Conditions shared by the study groups
- Route
- p.o.
- Treatment course
- anamorelin (30 mg·kg−1 for 4 weeks) were administered daily p.o.
- Anamorelin 30 mg·kg−1
- Model: 23‐month‐old C57BL/6 mice
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Anamorelin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Chemical Administration (S16, S19); Results > KARIs Attenuate Age‐Related Decline in Skeletal Muscle Mass and Function in Mice (S93)
body weight: body weight; comparator: PBS‐treated controls — Materials and Methods > Chemical Administration (S19); Results > KARIs Attenuate Age‐Related Decline in Skeletal Muscle Mass and Function in Mice (S93)
Anamorelin 30 mg·kg−1 · Materials and Methods > Chemical Administration (S19); Results > KARIs Attenuate Age‐Related Decline in Skeletal Muscle Mass and Function in Mice (S93)
Anamorelin and Body Weight in Non-Cancer-Bearing Mice
Animal study · Non-cancer-bearing mice; male C3H mice; Six mice were included in each treatment group [2]
Non-cancer-bearing male mice received Anamorelin by oral gavage, with vehicle-only animals as controls. The body-weight result was reported as non-significant.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- 2 weeks; Day 14
- Vehicle
- 200 μL sterile water
- Anamorelin 20 mg/kg/day
- Model: Non-cancer-bearing mice; male C3H mice; Six mice were included in each treatment group
- Reported limits: Removed after verification: value.
Methods and source locations
Compound reported in the paper: Anamorelin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
4. Materials and Methods > 4.2. Animal Experiments (S51, S55, S57, S58, S59); Table 1 (T1.h1, T1.r2, T1.r3)
Body Weight (gram): Body Weight (gram); comparator: non-treated control (vehicle only) — Table 1 (T1.h1, T1.r2, T1.r3)
Anamorelin 20 mg/kg/day · 4. Materials and Methods > 4.2. Animal Experiments (S57, S58, S59); Table 1 (T1.h1, T1.r2, T1.r3)
Anamorelin and body weight in tumor-bearing nude mice
Animal study · female athymic nude mice (nu/nu, Harlan); A549 tumor cells; 15 mice each [3]
Female athymic nude mice bearing A549 tumors received Anamorelin orally once daily. The higher tested doses produced statistically significant increases in percentage body-weight change compared with water controls; the lowest tested dose did not.
Conditions shared by the study groups
- Route
- p.o.
- Treatment course
- From day 3 to day 30 (28-day treatment period); once daily
- Vehicle
- de-ionized (DI) water
- Anamorelin 3, 10, or 30 mg/kg
- Model: female athymic nude mice (nu/nu, Harlan); A549 tumor cells; 15 mice each
Methods and source locations
Compound reported in the paper: Anamorelin
Evidence for Anamorelin as the hydrochloride form reported in the paper, not the free base/neutral form supplied as A12346; no salt equivalence, dose conversion or lot validation.
Materials and methods > Test agents (S2); Materials and methods > Mice (S4); Materials and methods > Tumor cell culture and implantation (S9, S10); Materials and methods > Treatment study design (S12, S16); Materials and methods > Endpoints (S24); Results > Effects of ghrelin and anamorelin on food consumption and body weight (S48, S49)
Percentage change in BW from days 3 to 30: Percentage change in BW from days 3 to 30; comparator: DI water p.o. — Materials and methods > Endpoints (S24); Results > Effects of ghrelin and anamorelin on food consumption and body weight (S48, S49)
Anamorelin 3, 10, or 30 mg/kg · Materials and methods > Treatment study design (S16); Results > Effects of ghrelin and anamorelin on food consumption and body weight (S48, S49)
Tumor Growth in Colon Tumor-Bearing Mice
Animal study · 8‐week‐old BALB/c mice [1]
BALB/c mice bearing CT26 tumors received Anamorelin by oral gavage. Anamorelin had no effect on tumor growth during treatment compared with PBS-treated controls.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- Nine days after tumour inoculation, when tumours became measurable, mice were treated orally with PBS, KARI compounds (10 or 30 mg·kg−1) or anamorelin (30 mg·kg−1) daily until Day 24.
- Anamorelin 30 mg·kg−1
- Model: 8‐week‐old BALB/c mice
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Anamorelin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Cancer Cachexia Mouse Model (S36, S38, S39, S40); Results > KARIs Improve Anorexia, Skeletal Muscle Loss and Functional Impairment in Cancer Cachexia Mice (S113, S114, S115)
tumour volume: tumour volume; comparator: CT26‐bearing mice treated with PBS — Materials and Methods > Cancer Cachexia Mouse Model (S40); Results > KARIs Improve Anorexia, Skeletal Muscle Loss and Functional Impairment in Cancer Cachexia Mice (S115)
Anamorelin 30 mg·kg−1 · Materials and Methods > Cancer Cachexia Mouse Model (S39); Results > KARIs Improve Anorexia, Skeletal Muscle Loss and Functional Impairment in Cancer Cachexia Mice (S113, S115)
